journal of men's health
Volume 5 , Pages S21-S25 , September 2008

Getting Urology involved in the treatment of men with erectile dysfunction, the metabolic syndrome and hypogonadism

References 

  1. Bansal TC, Guay AT, Jacobson J, Woods BO, Nesto RW. Incidence of metabolic syndrome and insulin resistance in a population with organic erectile dysfunction. J Sex Med. 2005;2:96–103
  2. Grover SA, Lowensteyn I, Kaouache M, Marchand S, Coupal L, DeCarolis E, et al. The prevalence of erectile dysfunction in the primary care setting: importance of risk factors for diabetes and vascular disease. Arch Intern Med. 2006;166:213–219
  3. Jackson G. The Metabolic Syndrome and Erectile Dysfunction: Multiple Vascular Risk Factors and Hypogonadism. Eur Urol. 2006;50(3):426–427
  4. Shabsigh R, Rajfer J, Aversa A, Traish AM, Yassin A, Kalinchenko SY, et al. The evolving role of testosterone in the treatment of erectile dysfunction. Int J Clin Pract. 2006;60:1087–1092
  5. Shabsigh R, Arver S, Channer KS, Eardley I, Fabbri A, Gooren L, et al. Sexual health as a portal to men's health: a problem turned around into an opportunity. Int J Clin Pract. 2008;62:179–181
  6. Gooren LJ, Saad F. Recent insights into androgen action on the anatomical and physiological substrate of penile erection. Asian J Androl. 2006;8:3–9
  7. Shabsigh R. Testosterone therapy in erectile dysfunction. Aging Male. 2004;7:312–318
  8. Shabsigh R, Perelman MA, Lockhart DC, Lue TF, Broderick GA. Health issues of men: prevalence and correlates of erectile dysfunction. J Urol. 2005;174:662–667
  9. Traish AM, Guay AT. Are androgens critical for penile erections in humans? Examining the clinical and preclinical evidence. J Sex Med. 2006;3:382–404discussion 404-387
  10. Kupelian V, Shabsigh R, Travison TG, Page ST, Araujo AB, McKinlay JB. Is there a relationship between sex hormones and erectile dysfunction? Results from the Massachusetts Male Aging Study. J Urol. 2006;176:2584–2588
  11. Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev. 2005;
  12. Black AM, Day AG, Morales A. The reliability of clinical and biochemical assessment in symptomatic late-onset hypogonadism: can a case be made for a 3-month therapeutic trial?. BJU Int. 2004;94:1066–1070
  13. Nieschlag E, Swerdloff R, Behre HM, Gooren LJ, Kaufman JM, Legros JJ, et al. Investigation, treatment and monitoring of late-onset hypogonadism in males. ISA, ISSAM, and EAU recommendations. Eur Urol. 2005;48:1–4
  14. Vermeulen A. Androgen replacement therapy in the aging male--a critical evaluation. J Clin Endocrinol Metab. 2001;86:2380–3237
  15. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999;84:3666–3672
  16. Gheorghiu I, Moshyk A, Lepage R, Ahnadi CE, Grant AM. When is bioavailable testosterone a redundant test in the diagnosis of hypogonadism in men?. Clin Biochem. 2005;
  17. Vermeulen A, Verdonck G. Representativeness of a single point plasma testosterone level for the long term hormonal milieu in men. J Clin Endocrinol Metab. 1992;74:939–942
  18. Tancredi A, Reginster JY, Luyckx F, Legros JJ. No major month to month variation in free testosterone levels in aging males. Minor impact on the biological diagnosis of ‘andropause’. Psychoneuroendocrinology. 2005;30:638–646
  19. Wang C, Catlin DH, Demers LM, Starcevic B, Swerdloff RS. Measurement of total serum testosterone in adult men: comparison of current laboratory methods versus liquid chromatography-tandem mass spectrometry. J Clin Endocrinol Metab. 2004;89:534–543
  20. Matsumoto AM, Bremner WJ. Serum testosterone assays--accuracy matters. J Clin Endocrinol Metab. 2004;89:520–524
  21. Nieschlag E, Swerdloff R, Behre HM, Gooren LJ, Kaufman JM, Legros JJ, et al. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations. Int J Androl. 2005;28:125–127
  22. Severi G, Morris HA, MacInnis RJ, English DR, Tilley W, Hopper JL, et al. Circulating steroid hormones and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2006;15:86–91
  23. Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med. 2004;350:482–492
  24. Calof OM, Singh AB, Lee ML, Kenny AM, Urban RJ, Tenover JL, et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci. 2005;60:1451–1457
  25. Rhoden EL, Morgentaler A. Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia. J Urol. 2003;170:2348–2351
  26. Kaufman JM, Graydon RJ. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol. 2004;172:920–922
  27. Kaufman J. A rational approach to androgen therapy for hypogonadal men with prostate cancer. Int J Impot Res. 2006;18:26–31
  28. Kaufman JM. The effect of androgen supplementation therapy on the prostate. Aging Male. 2003;6:166–174
  29. Gaylis FD, Lin DW, Ignatoff JM, Amling CL, Tutrone RF, Cosgrove DJ. Prostate cancer in men using testosterone supplementation. J Urol. 2005;174:534–538discussion 538
  30. Nieschlag E, Swerdloff R, Behre HM, Gooren LJ, Kaufman JM, Legros JJ, et al. Investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male. 2005;8:56–58
  31. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, et al. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2006;91:1995–2010
  32. Saad F, Gooren LJ, Haider A, Yassin A. A Dose Response Study of Testosterone on Sexual Dysfunction and on Features of the Metabolic Syndrome Using Testosterone Gel and Parenteral Testosterone Undecanoate. J Androl. 2007;
  33. Jacobeit JW, Gooren LJ, Schulte HM. Long-acting intramuscular testosterone undecanoate for treatment of female-to-male transgender individuals. J Sex Med. 2007;4:1479–1484

PII: S1875-6867(08)00072-9

doi: 10.1016/j.jomh.2008.03.011

journal of men's health
Volume 5 , Pages S21-S25 , September 2008

Article Tools